Form 8-K - Current report:
SEC Accession No. 0001104659-22-099298
Filing Date
2022-09-12
Accepted
2022-09-12 17:09:29
Documents
13
Period of Report
2022-09-09
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2225662d1_8k.htm   iXBRL 8-K 32464
2 EXHIBIT 10.1 tm2225662d1_ex10-1.htm EX-10.1 75814
  Complete submission text file 0001104659-22-099298.txt   299689

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA anvs-20220909.xsd EX-101.SCH 3039
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20220909_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20220909_pre.xml EX-101.PRE 22599
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2225662d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 221239210
SIC: 2834 Pharmaceutical Preparations